© 2024 Myocardial Solutions Inc. All rights reserved.
MORRISVILLE, N.C., January 14, 2022 – This article addresses the importance of having a new tool like MyoStrain® to detect patients with preserved Left Ventricle Ejection Fraction (LVEF).
Traditional diagnostic metrics are affected by the hearts compensatory mechanisms which hide the true health of the myocardium.
By measuring segmental strain, MyoStrain can distinguish weaker and stronger areas of the heart because it is less effected by the heart’s compensatory mechanisms.
Access to the publication is available here.
Korosoglou G, Giusca S and Kelle S (2022) SGLT2 Inhibition in HFpEF. Do We Need More Quantitative and Load Independent Metrics to Understand the Results of the EMPEROR-Preserved Trial? Front. Cardiovasc. Med. 8:822968. https://doi.org/10.3389/fcvm.2021.822968
PR@myocardialsolutions.com
919.677.8100
Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, MRI-based heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.
To learn more about MyoStrain, visit myocardialsolutions.com or connect with us on LinkedIn and Twitter @myocardialsoln.
808 Aviation Pkwy, Suite 700 | Morrisville, NC 27560 | myocardialsolutions.com | ph: +1.919.677.8100
© Copyright 2022 Myocardial Solutions Inc. All rights reserved. MyoStrain® and the MyoHealthTM
Score are among the trademarks of Myocardial Solutions.
